CGA Response: Fundamentals of Multi-Cancer Early Detection
Monday, March 29, 2021
12:00 PM – 1:00 PM ET
This virtual program is at 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain, and 9:00AM Pacific.
The Latest Approaches to the Care of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas Including the Use of Bispecific Antibodies
This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
